International application No.

PCT/JP2005/003693

A CLASSIEIC	CATION OF SUBJECT MATTER	· · · · · · · · · · · · · · · · · · ·	
Int.Cl	C12N15/09, A61K31/7088, 39/00	0, 45/00, 48/00, A61P37	/04
According to Int	ernational Patent Classification (IPC) or to both nationa	al classification and IPC	
B. FIELDS SE	ARCHED		
Minimum docun Int . Cl	nentation searched (classification system followed by classification system system followed by classification system system system followed by classification system syst	assification symbols) D , 45/00, 48/00, A61P37,	/04
	searched other than minimum documentation to the exte		
Electronic data b	pase consulted during the international search (name of a /MEDLINE/WPIDS (STN), REGISTRY/C	data base and, where practicable, search te	rms used)
C. DOCUMEN	NTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
Y	JP 2003-510290 A (Coley Phar	maceutical Group,	1-7
	Inc.), 18 March, 2003 (18.03.03), Full text & WO 2001/22990 A2 & EP		
Y	US 2003/50268 Al (KRIEG, A.M 13 March, 2003 (13.03.03), Full text (Family: none)	. et al.),	1-7
У	US 2003/87848 Al (BRATZLER, 08 May, 2003 (08.05.03), Full text (Family: none)	R.L. et al.),	1-7
× Further do	Documents are listed in the continuation of Box C.	See notes family games	
	<u></u>	See patent family annex.	
Special categories of cited documents: A document defining the general state of the art which is not considered to be of particular relevance E earlier application or patent but published on or after the international		"T" later document published after the inte date and not in conflict with the applica- the principle or theory underlying the in "X" document of particular relevance; the con-	ation but cited to understand nvention
filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other "Y" document of particular relevance; the claimed invention or other "Y"		dered to involve an inventive	
1	on (as specified) eferring to an oral disclosure, use, exhibition or other means	considered to involve an inventive combined with one or more other such	step when the document is documents, such combination
"P" document published prior to the international filing date but later than the priority date claimed		being obvious to a person skilled in the "&" document member of the same patent to	
Date of the actual completion of the international search 24 May, 2005 (24.05.05)		Date of mailing of the international sear 14 June, 2005 (14.0	
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer	
·		Telephone No.	
Facsimile No.		To the description of the property of the prop	

International application No.
PCT/JP2005/003693

	PCT	r/JP2005/003693
(Continuation	n). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passag	es Relevant to claim No.
Y	KURAMOTO, E. et al., "Oligonucleotide Sequence Required for Natural Killer Cell Activation", Jpn.J.Cancer Res., (1992), Vol.83, pages 1128 1131, full text	
Y	WO 2004/000351 Al (CYTOS BIOTECHNOLOGY AG.), 31 December, 2003 (31.12.03), Full text (Family: none)	5-7
А	KRUG, A. et al., "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/bata in plasmacytoid dendritic cells", Eur.J.Immunol., (2001), Vol.31,	1-7
	pages 2154 to 2163	,
		+

International application No.

PCT/JP2005/003693

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
1. Claims N	search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Nos.: they relate to subject matter not required to be searched by this Authority, namely:
	Nos.: they relate to parts of the international application that do not comply with the prescribed requirements to such an lat no meaningful international search can be carried out, specifically:
3. Claims N	Nos.: they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
Although in Gn-(G/C)A stimulati stimulati to 9)", is et al., "I of IFN-alp Vol.31, p Such bes 1. As all rec claims. 2. As all sea any addit 3. As only s	Searching Authority found multiple inventions in this international application, as follows: h it appears that the matter common to all of claims 1 to 7 resides "immune stimulating oligonucleotides comprising CGATCGT(G/C)-G(10-n): n=1 to 9)", it is clarified that an immune and oligonucleotide G4-GACGATCGTG-G6, which is one of "immune and oligonucleotides comprising Gn-(G/C)ACGATCGT(G/C)-G(10-n): n=1 is not novel because of having been described in document (KRUG, A. Identification of CpG oligonucleotide sequences with high induction pha/beta in plasmacytoid dendritic cells", Eur. J. Immunol., (2001), pp. 2154-2163) disclosed in the description as prior art. ing the case, the inventions according (continued to extra sheet) quired additional search fees were timely paid by the applicant, this international search report covers all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of the required additional search fees were timely paid by the applicant, this international search report covers see claims for which fees were paid, specifically claims Nos.:
restricted The part	ired additional search fees were timely paid by the applicant. Consequently, this international search report is d to the invention first mentioned in the claims; it is covered by claims Nos.: as relating to an immune stimulating oligonucleotide comprising the mence of SEQ ID NO: 7 in claims 1 to 7. The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

~ : T

International application No.

PCT/JP2005/003693

Continuation of Box No.III of continuation of first sheet(2)

to claims 1 to 7 are divided into eight groups of inventions respectively having special technical features in "immune stimulating oligonucleotides comprising the base sequences of SEQ ID NOS:7, 1 to 6 and 8".